News articles about MabVax Therapeutics (NASDAQ:MBVX) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MabVax Therapeutics earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.1695926365144 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:

MabVax Therapeutics (NASDAQ MBVX) traded up $0.02 on Tuesday, reaching $0.82. The company had a trading volume of 139,400 shares, compared to its average volume of 250,366. MabVax Therapeutics has a twelve month low of $0.43 and a twelve month high of $3.65. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 0.80.

MabVax Therapeutics (NASDAQ:MBVX) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter. research analysts expect that MabVax Therapeutics will post -3.01 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “MabVax Therapeutics (MBVX) Getting Somewhat Positive News Coverage, Report Finds” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at

About MabVax Therapeutics

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Insider Buying and Selling by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with's FREE daily email newsletter.